Tisagenlecleucel CAR-T for relapsed/refractory diffuse large B-cell lymphoma; one therapy, two clinical presentations: urgent need to design adverse event predictors.

The article compares the first two cases of patients treated with tisagenlecleucel at the Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw in Warsaw, Poland. Topics include the different clinical presentations developed by the two patients after chimeric antigen receptor (CAR)-T infusion, clinical course of patients, and an adverse event (AE) prediction concept developed by research teams worldwide.